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Willebrand factor type C (VWC), thrombospondin type 1 repeats (TSP-1), and C-terminal cystine knot (CT); and each of these modules has different binding partners and seems to regulate the multiple functions of CCN2 [1] . The CT domain of CCN2 interacts directly with fibronectin and enhances cell adhesion of chondrocytes through binding to integrin α5β1 [10] . This domain also binds to integrin α5β1 to promote adhesion and migration of pancreatic stellate cells [11] .
Furthermore, it induces adhesion of hepatic cells by direct binding to the integrin receptor αvβ3 and to heparan sulfate proteoglycan through its C-terminal heparin-binding domain [12] . There are also reports indicating that CCN2 signaling occurs through low-density lipoprotein receptor-related protein-1 (LRP-1) [13] [14] [15] . Other studies show that CCN2 directly binds to bone morphogenetic protein-4 (BMP-4) and transforming growth factor-β (TGF-β) through its VWC module and prevents or enhances their binding to their own receptors [16] . Moreover, CCN2 binds vascular endothelial growth factor (VEGF) and inhibits its angiogenic effect [17] . There also is a report showing that CCN2 binds to aggrecan, which is a major marker of differentiated phenotype of chondrocytes, through its N-terminal IGFBP and VWC modules and that this binding may be related to the CCN2-enhanced production and secretion of aggrecan by chondrocytes [18] .
In order to identify additional extracellular or cell-surface targets for CCN2 that may be involved in the regulatory functions of CCN2 in chondrocytes, we searched for CCN2-binding proteins by using the yeast two-hybrid screening assay. A cDNA library derived from human chondrosarcoma-derived chondrocytic cell line HCS-2/8 was screened for products binding to CCN2, since this cell line has a differentiated phenotype similar to that of normal chondrocytes in terms of aggrecan and cartilage collagen secretion and integrin expression profiles [19] . We found CCN2 and CCN3 as binding partners of CCN2, indicating that CCN2 forms homotypic and heterotypic dimers with CCN2 and CCN3, respectively. CCN3, also a CCN family protein, is highly expressed in the nervous system, blood vessels, and musculoskeletal system as well as in pre-and early hypertrophic chondrocytes and osteoblasts [1, 20, 21] . The functions of CCN3 protein among these different tissues are not yet well defined. Although CCN3 was originally described as being antiproliferative [22] and its expression associated with differentiation and growth arrest in Wilm's tumor [23] , chondrosarcomas [24] , and rhabdomyosarcomas [25] , more recent data correlate CCN3 with an increased proliferative index of 3T3 fibroblasts [26] and prostate tissue samples [27] . Both CCN2 and CCN3 are expressed in the early hypertrophic to pre-hypertrophic zone of the growth plate in cartilage; and CCN2 enhances the expression of ECMs components, whereas CCN3 suppresses it in cultured growth plate chondrocytes [20] .
There seems to be some correlation between CCN2 and CCN3; however, the functional and physiological interaction between these 2 proteins had not been elucidated at all. In the present study, we show for the first time that (1) CCN2 bound to CCN2 through its IGFBP, VWC, and CT domains,
CCN2-interaction to CCN3 in chondrocytes
but not TSP-1 domain, and to CCN3 only via its VWC and CT domains; and (2) CCN2 rescued chondrocytes from CCN3-induced suppression of aggrecan and col2a1 expression. Inhibition of CCN2-CCN2 binding suppressed the expression of aggrecan, whereas promotion of CCN2-CCN3 binding enhanced it.
Results

Identification of CCN2 and CCN3 as CCN2 dimerization partners
Using yeast two-hybrid screening to search for proteins that directly interacted with full-length CCN2 (amino acid residues 27-349), we obtained several clones from a HCS-2/8 human chondrocytic cell cDNA library that encoded CCN2 and CCN3, indicating homotypic and heterotypic dimerization of CCN2. To confirm direct interactions between CCN2 and CCN2 or between CCN2 and CCN3, we used several methods. First, to identify the CCN2 interaction sites in CCN2 or CCN3, full-length, N-terminal, C-terminal, and individual domains of CCN2 or CCN3 were expressed in AH109 yeast cells as GAL4-transactivation domain (GAL4-AD)-fusion proteins, whereas full-length CCN2 was co-expressed as a GAL4-DNA binding domain (GAL4-BD)-fusion protein ( Fig.1 A) . Interactions between CCN2 or CCN3 fragments and full-length CCN2 were monitored as growth of yeast transformants in selection media (SD/-Ade, -His, -Leu, -Trp).
Self-interaction with full-length CCN2 was observed after co-transformation with CCN2 vectors expressing IGFBP, VWC, and/or CT, but not when the TSP-1 domain alone was tested. Interaction with CCN3 fragments was seen with vectors expressing the VWC or CT domain, but not with those expressing the IGFBP or TSP-1 domain (Fig.1 A) .
The difference in binding strength between full-length CCN2 (CCN2 full ) and IGFBP domain of CCN2 (CCN2 I ), and between CCN2 full and IGFBP domain of CCN3 (CCN3 I ), was estimated by measuring the β-galactosidase activity of the reporter gene in yeast expressing full-length CCN2 (GAL-BD/CCN2 full ), standardizing it to the protein concentration, and comparing it with the β-galactosidase activity obtained after co-transformation with the pGADT7 empty vector (mock, Fig.1 B) . CCN2 I showed almost the same strength of binding to CCN2 full as CCN2 full , whereas the binding of CCN3 I to CCN2 full was significantly lower than that of CCN3 full or CCN2 I to CCN2 full ( Fig.1 B) . These results indicate that among the 4 domains in CCN2, the IGFBP, VWC, and CT domains exhibited direct homotypic interaction with CCN2, whereas only the VWC and CT domains of CCN3 showed direct interaction with full-length CCN2.
CCN2 directly interacts with CCN2 and CCN3 in vitro.
For in vitro pull-down experiments using glutathione-Sepharose resin, recombinant His 6 -tagged CCN2-interaction to CCN3 in chondrocytes CCN2 (His-CCN2) and GST-fused CCN3 (GST-CCN3) were prepared as E.coli cell lysates.
Immunoblotting of the precipitates with anti-His and anti-GST antibody largely confirmed the yeast two-hybrid assay results (Fig.2 A) : His-CCN2 was effectively pulled down in the presence of GST-CCN3. We further confirmed the binding between CCN2 and CCN2 or between CCN3 and CCN2 by performing a solid-phase binding assay (Fig.2 B) . Purified CCN2 or GST-CCN3 was immobilized on the plates, and increased amounts of biotinylated recombinant CCN2 (rCCN2) were used for binding. Biotinylated rCCN2 bound to immobilized rCCN2 or GST-CCN3 in a dose-dependent manner (Fig.2 B) . Finally, the dissociation constant of CCN2 to CCN2 or to CCN3 was determined by using surface plasmon resonance (SPR) analysis (Fig.2 C) . rCCN2 protein was immobilized on a sensor tip as a ligand and rCCN2 and rCCN3 were used as analytes at concentrations of 4, 8, 16, 32, and 64 nM. Calculated from sensorgram analysis, the K d value was 1.17x10 -9 M for the CCN2-CCN2 interaction and 1.95×10 -9 M for the CCN2-CCN3 one (Fig.2 C) .
These data indicate that CCN2 underwent a homotypic interaction and a heterotypic one with CCN3
with a similar binding affinity.
Endogenous CCN2 and CCN3 interact and co-localize in chondrocytic HCS-2/8 cells.
To investigate the endogenous interaction between CCN2 and CCN3, we coimmunoprecipitated endogenous CCN2 with CCN3 from HCS-2/8 cell lysates using anti CCN2 antibody. CCN3 was effectively immunoprecipitated with an anti-CCN2 antibody (Fig.3 A) , but not with control IgG..
Indirect immunostaining of endogenous CCN2 (red) and CCN3 (green) with spcific antibodies showed subcellular colocalization inside of the permeabilized cells with TritonX-100 and on cell surface without permeabilization treatment (Fig.3 B) .
Ectopically overexpressed CCN2 and CCN3 interact and co-localize in COS7 cells.
To confirm the interaction between CCN2 and CCN3 in vivo, we co-expressed GFP-fused CCN2
and Halo-tagged CCN3 in COS7 cells. GFP or GFP-CCN2 was immunoprecipitated with anti-GFP antibody from cell lysates with binding proteins, and the precipitated proteins were analyzed by using anti-Halo antibody. Halo-CCN3 (arrow in lane 8 of Fig.4 A) was pulled down effectively only after co-expression with GFP-CCN2 (Fig.4 A) . The subcellular localization of GFP-CCN2 and Halo-CCN3 largely overlapped when the cells were directly analyzed by GFP (green) fluorescence and the fluorescence (red) from the dye binding to Halo (Fig.4 B) . and rCCN3 abolished the repression caused by rCCN3 (Fig.5 A) , and this abolishment occurred in a CCN2 dose-dependent manner (Fig.5 B) . Similar results were obtained in the mouse primary chondrocytes isolated from rib cartilage (data not shown). These data suggest that CCN2 and CCN3
cooperatively regulated the gene expression of extracellular matrices such as aggrecan and col2a1 mRNA in chondrocytes. Among the CCN family members, CCN3 acts as a negative regulator of CCN2 in the fibrotic pathway of model of renal disease [29, 30] ; and the addition of recombinant CCN3 slightly decreases the expression of extracellular matrix genes in the growth-plate chondrocytes, in contrast to CCN2, which strongly up-regulates those genes [20] . Furthermore, CCN2 down-regulates CCN3 expression in growth-plate chondrocytes [20] . In epiphyseal chondrocytes, however, CCN3 promotes the expression of matrix genes and stabilizes the phenotype of articular cartilage [31] . Here we show for the first time homotypic and heterotypic interactions of CCN2 with itself and CCN3, respectively, and provide evidence that homotypic and heterotypic dimers of CCN2 may regulate the production of chondrocytic extracellular matrices in a different manner.
Addition of 11H3 changes
A previous study indicated that the CT domain of CCN3 interacted weakly with full length CCN3
and CCN2 in their yeast two-hybrid study [32] . In our present study, not only the CT domain of CCN3, but also the VWC domain had the ability to bind to full-length CCN2. Furthermore, the specificity of the homotypic and heterotypic interactions of CCN2 was substantiated by the yeast The physiological effects of homomeric and heteromeric interaction between CCN2 and CCN2, and CCN2 and CCN3 on the production of extracellular matrix of chondrocytes were monitored in human chondrocytic cell line, HCS-2/8 by performing real-time PCR, since CCN2 is an enhancer of aggrecan and col2a1 gene expression in chondrocytes [1, 8] . In contrast, CCN3 down-regulates the expression of extracellular matrix genes in growth-plate chondrocytes [20] , TGF-β-stimulated Col1 promoter activity in a renal fibrosis model [29] , and BMP-2-induced osteocalcin production through inhibition of the Notch signaling cascade [35] . On the other hand, CCN3 enhances matrix production in articular chondrocytes [31] , and stimulates BMP-4 gene expression and bone mineralization in osteoblasts [36] . According to our results, however, CCN2 enhanced, whereas CCN3
down-regulated, aggrecan expression. This down-regulation was partially reversed by CCN2
treatment. CCN2 dose-dependently increased the amount of aggrecan and col2a1 gene expression Our results indicate that it is the IGFBP domains of CCN2 and CCN3 that make the difference between the homotypic or heterotypic complex formation. CCN2 interacts with many extracellular signaling molecules; e.g., it binds to TGF-β, TGF-βRI and II [37] , BMP-2 [38] , and BMP-4 [16].
Furthermore, CCN2 modulates Wnt signal pathways [39] , as well as the activity of a Wnt inhibitory protein (Wif-1) [40] . CCN3 may also have a role in the modulation of those signaling pathways by interacting with CCN2, but the mechanisms remain to be elucidated.
In CCN2-deficient mice, which show incomplete endochondral ossification, the expression level of CCN3 is strongly enhanced [20] . Two different lines of CCN3-deficient mice were developed.
One of them, the nov del3-/-mutant mice, which produce no full-length CCN3 protein and express CCN3 without its VWC domain at a barely detectable level, shows abnormal skeletal and cardiac development [41] . The other line, which is completely CCN3 null mice, show enhanced neointimal thickening compared with the wild type, confirming that CCN3 suppresses angiogenesis and fibrosis.
These results indicate that CCN2 and CCN3 seem to mutually regulate their activities and expression levels. However, in our experiments the expression level of CCN2 did not alter after addition of 
Expression and purification of GST-CCN3 and rhCCN2
For preparation of purified recombinant GST-CCN3 protein, the ccn3 gene was amplified without its signal peptide by PCR with primers 5'-ATACGGATCCACTCAGCGCTGCCCTCCCCAGTG-3'
and 5'-ATCCGAATTCTTACATTTTCCCTCTGGTAGTCTTC-3', and subcloned into the pGEX-2TK vector (GE Healthcare), which carries a GST-tag at its BamHI/EcoRI sites. The recombinant plasmid was sequenced to ensure the absence of mutations. BL21(DE3)pLysS
Escherichia coli cells (Novagen) were then transfected with the plasmid for expression of recombinant proteins. The expressed GST-CCN3 protein was purified with Glutathione-Sepharose 4B agarose (GE Healthcare) as described previously [43] . The purified protein was dialyzed against phosphate-buffered saline (PBS). In some experiments, rCCN3 (Abnova) was used. Preparation and purification of CCN2 carrying a His 6 -tag were performed as described previously [18] . In some experiments, rhCCN2 (BioVendor Laboratory Medicine) was used.
In vitro binding assay
E.coli expressing rhCCN2 or GST-CCN3 were harvested and sonicated in co-immunoprecipitation (co-IP) buffer [20 mM Tris/HCl (pH 8.0), 25 mM NaCl, 1mM MgCl 2 , 1 mM EGTA, 1% Triton X-100, 1 mM DTT and 1 mM PMSF]. After removal of cell debris, both cell lysates were mixed at 4°C to form CCN2-CCN3 complex. The complexes were then incubated with Glutathione-Sepharose 4B for 1 h at 4°C. The beads were subsequently washed with co-IP buffer with 10% glycerol, after which the bead-protein complexes were subjected to SDS-PAGE and analyzed by Western blotting using an anti-His tag antibody (BETHYL) and GST-tag antibody (GE Healthcare).
Solid-phase binding assay and antibody against CCN2
Wells of an ELISA plate were coated with 100 μl of 500 ng/ml recombinant CCN2 (BioVendor Laboratory Medicine) or GST-CCN3 in 50 mM NaHCO 3 buffer (pH 9.6) at 4°C overnight, and blocked with 200 μl of binding buffer [50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2% BSA, 0.05% Tween20] for 3 h at 37°C. Biotinylated CCN2 with or without 11H3 antibody was added to the wells in a total volume of 100 μl of binding buffer and incubated for 6 h at 37°C. Next, the wells were washed with binding buffer and then incubated with 100 μl of streptavidin-HRP (R&D Systems, MN). Bound HRP was monitored by using a TMD peroxidase substrate kit (Bio-Rad, CA). As control experiments, wells were coated with BSA or GST. The mouse monoclonal antibody used in these experiments was raised against the VWC domain of CCN2 and kindly supplied by Dr. Y.
Seto (Nippon Flour Mills Co., Ltd., Japan).
Surface plasmon resonance analysis (BIAcore)
Binding of CCN2 to CCN2 or CCN3 was analyzed by surface plasmon resonance with the BIAcore X instrument (GE Healthcare). rhCCN2 (1. 
